BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of serious diseases. The company is headquartered in Israel and is publicly traded on the NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol BLRX.
History[edit | edit source]
BioLineRx was founded in 2003 with the aim of identifying, in-licensing, and developing promising therapeutic candidates. The company has since built a diverse pipeline of clinical and preclinical programs, primarily in the fields of oncology and immunology.
Pipeline[edit | edit source]
BioLineRx's pipeline includes several key programs:
- Motixafortide (BL-8040): A CXCR4 antagonist being developed for the treatment of various types of cancer, including acute myeloid leukemia (AML) and solid tumors. Motixafortide is also being investigated for use in stem cell mobilization for hematopoietic stem cell transplantation.
- AGI-134: An immunotherapy agent designed to induce a systemic anti-tumor response by targeting the alpha-Gal epitope on cancer cells.
- BL-5010: A topical treatment for non-surgical removal of benign skin lesions.
Research and Development[edit | edit source]
BioLineRx collaborates with leading academic institutions, hospitals, and biotechnology companies to advance its research and development efforts. The company employs a rigorous selection process to identify and in-license promising drug candidates, which are then developed through clinical trials.
Partnerships[edit | edit source]
BioLineRx has established partnerships with several pharmaceutical companies and research organizations to enhance its development capabilities and expand its pipeline. Notable partners include Genentech, a member of the Roche Group, and Merck & Co..
Financials[edit | edit source]
BioLineRx is funded through a combination of public and private investments. The company has raised capital through various funding rounds and maintains a presence on both the NASDAQ and the Tel Aviv Stock Exchange.
See also[edit | edit source]
References[edit | edit source]
External links[edit | edit source]
BioLineRx
| Type | Public |
|---|---|
| Traded as | NASDAQ: BLRX , TASE: BLRX |
| Industry | Biopharmaceutical |
| Website | [www |
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
